In preclinical models of HER2-positive breast cancer, entinostat exhibited combinational synergistic effects with the HER2/epidermal growth factor receptor (EGFR) dual tyrosine kinase inhibitor to inhibit tumor progression, sensitizing tumor cells to anti-HER2 treatments [139]. The gene discussed is ERBB2; the disease is breast carcinoma.